Journals / art / 2018 / Cilt: 33 - Sayı: 3

Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations

Journal
art
Pages
251–272
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Expert opinion of the TLAR for the treatment of RA was composed for practices in Turkish rheumatology and/or physical medicine and rehabilitation clinics.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to report the assessment of the Turkish League Against Rheumatism (TLAR) expert panel on the compliance and adaptation of the European League Against Rheumatism (EULAR) 2016 recommendations for the management of rheumatoid arthritis (RA) in Turkey.
📊
Key Findings & Data:Patients and methods: The EULAR 2016 recommendations for the treatment of RA were voted by 27 specialists experienced in this field with regard to participation rate for each recommendation and significance of items.
💡
Conclusion & Impact:Conclusion: Expert opinion of the TLAR for the treatment of RA was composed for practices in Turkish rheumatology and/or physical medicine and rehabilitation clinics.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to report the assessment of the Turkish League Against Rheumatism (TLAR) expert panel on the compliance and adaptation of the European League Against Rheumatism (EULAR) 2016 recommendations for the management of rheumatoid arthritis (RA) in Turkey. Patients and methods: The EULAR 2016 recommendations for the treatment of RA were voted by 27 specialists experienced in this field with regard to participation rate for each recommendation and significance of items. Afterwards, each recommendation was brought forward for discussion and any alteration gaining ≥70% approval was accepted. Also, Turkish version of each item was rearranged. Last version of the recommendations was then revoted to determine the level of agreement. Levels of agreement of the two voting rounds were compared with Wilcoxon signed-rank test. In case of significant difference, the item with higher level of agreement was accepted. In case of no difference, the changed item was selected.Results: Four overarching principles and 12 recommendations were assessed among which three overarching principles and one recommendation were changed. The changed overarching principles emphasized the importance of physical medicine and rehabilitation specialists as well as rheumatologists for the care of RA patients in Turkey. An alteration was made in the eighth recommendation on treatment of active RA patients with unfavorable prognostic indicators after failure of three conventional disease modifying anti-rheumatic drugs. Remaining principles were accepted as the same although some alterations were suggested but could not find adequate support to reach significance. Conclusion: Expert opinion of the TLAR for the treatment of RA was composed for practices in Turkish rheumatology and/or physical medicine and rehabilitation clinics.

🔖

Cite This Article

ATAMAN, Ş., SUNAR, İ., YILMAZ, G., BODUR, H., NAS, K., AYHAN, F. F., AKGÜL, Ö., AKINCI, A., ALTAY, Z., BİRTANE, M., BUĞDAYCI, D. S., ÇAPKIN, E., ÇEVİK, R., ÇİMEN, Y. G., DURUÖZ, M. T., ELHAN, A. H., GÜRER, G., KAÇAR, C., KAMANLI, A., KAPTANOĞLU, E., KAYA, T. (2018). Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. art, Cilt: 33 - Sayı: 3, 251–272. https://ajindex.com/articles/156444

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007;66:358-63.
  2. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54:3761-73. O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 2010;69:1823-6. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. Arthritis Rheum 2009;60:2262-71.
  3. Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol 2013;31(4 Suppl 78):S4-8. Naredo E, Valor L, De la Torre I, Montoro M, Bello N, Martinez-Barrio J, et al. Predictive value of doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 2015;54:1408-14.
  4. Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional dmard therapy in rheumatoid arthritis: Current evidence and future directions. Ann Rheum Dis 2016;75:1428-37.
  5. Lau CS, Gibofsky A, Damjanov N, Lula S, Marshall L, Jones H, et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int 2017;37:1789-98.
  6. Henaux S, Ruyssen-Witrand A, Cantagrel A, Barnetche T, Fautrel B, Filippi N, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 2018;77:515-22.
  7. Yasuda S, Ohmura K, Kanazawa H, Kurita T, Kon Y, Ishii T, et al. Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (matador) - a prospective, multicenter, single arm pilot clinical trial. Mod Rheumatol 2017;27:930-7.
  8. Smolen JS, Nash P, Durez P,